BerGenBio to present new NSCLC and AML clinical data and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019
· Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019 · Non-Small-Cell Lung Cancer (NSCLC) trial of bemcentinib in combination with pembrolizumab, data to be presented includes safety, response rates and overall survival · Acute Myeloid Leukaemia (AML) trial of bemcentinib in combination with low dose AraC chemotherapy or decitabine reported safety and rapid, durable complete response ratesBergen, Norway, 15 May 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase